Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 02/21/2014) - In an international randomized phase III trial, previously untreated patients with chronic lymphocytic leukemia (CLL) and other health conditions who received a combination of obinutuzumab (Gazyva™) and chlorambucil (Leukeran®) lived longer without their disease getting worse (progression-free survival) than patients who received chlorambucil alone. Patients who received the combination also had better overall survival than those who received chlorambucil alone, and they were more likely to have all signs of their disease disappear (complete response). Patients who received obinutuzumab plus chlorambucil also had longer progression-free survival and higher complete response rates than patients who received rituximab (Rituxan®) plus chlorambucil. Overall survival did not differ between the two groups.
NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy
(Posted: 12/05/2013) - Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a NIH-supported randomized controlled clinical trial.
Combination of Nab-Paclitaxel and Gemcitabine Improves Survival in Patients with Metastatic Pancreatic Cancer
(Posted: 11/15/2013) - In an international randomized phase III trial, patients with metastatic pancreatic cancer who were treated with a combination of albumin-bound paclitaxel (nab-paclitaxel [Abraxane®]) and gemcitabine (Gemzar®) lived longer than patients who were treated with gemcitabine alone. Patients who received both drugs also lived longer without their disease getting worse (progression-free survival).
Pomalidomide plus Low-Dose Dexamethasone Improves Survival for Patients with Multiple Myeloma
(Posted: 09/19/2013) - Results from a randomized phase III trial show that the combination of pomalidomide (Pomalyst®) and low-dose dexamethasone may benefit some patients with multiple myeloma that has progressed (worsened) despite other treatments. Patients who received the combination therapy lived longer without the disease getting worse than patients who received high-dose dexamethasone alone. Overall survival was also improved in the group that received the combination therapy compared with the other group.
Finasteride Reduces the Risk of Low-Grade Prostate Cancer in Men 55 and Older
(Posted: 08/28/2013) - Long-term follow-up results from a phase III trial show that regular use of finasteride (Proscar®) for up to 7 years decreased the risk of low-grade prostate cancer in men age 55 and older compared with that in men who received a placebo. Although high-grade cancers were more common in the finasteride group, the finasteride and placebo groups had similar 15-year overall survival rates.